A Popular Anti-Aging Treatment Damages Brain Cells in Mice
Dasatinib and quercetin — the most widely used senolytic combination in longevity circles — causes damage to specific brain regions in mice that closely resembles what is seen in multiple sclerosis.
Senolytics are drugs designed to eliminate so-called ‘zombie cells’ — senescent cells that no longer divide but refuse to die, instead secreting inflammatory signals that damage surrounding tissue. The combination of dasatinib, a cancer drug, and quercetin, a plant-derived antioxidant, is the most studied senolytic pairing and has become something of a staple in the self-experimentation community. The logic seemed sound: clear out the damaged cells, reduce inflammation, slow aging. A new study published in April 2026 complicates that picture considerably.
Researchers found that in mice, the treatment specifically targets stem cells in the brain responsible for producing myelin — the protective sheath around nerve fibers that allows them to transmit signals efficiently. When these stem cells are eliminated as part of the senolytic sweep, the brain loses a critical repair mechanism. The resulting damage looks structurally similar to the lesions found in multiple sclerosis patients. That was not what anyone expected to find.
Not all old cells are the enemy
The core problem is cellular indiscrimination. Senolytics do not distinguish between harmful zombie cells and those still performing useful functions. In the brain, oligodendrocyte precursor cells — the cells that generate myelin — appear to be particularly vulnerable. When the treatment removes them as collateral damage, the brain’s self-repair capacity diminishes. It is a striking example of how intervening in one biological process can inadvertently disrupt another.
This does not automatically mean the same damage occurs in humans. Mouse models are imperfect proxies for human biology, and the doses used in animal studies do not always correspond to what people actually take. But the findings add a concrete neurological concern to a list of unknowns that researchers have been flagging for years. Dasatinib is a powerful chemotherapy agent with known side effects — it was never designed as a wellness supplement. The fact that it is being used as one, often without medical supervision, is itself a reason for pause.
An open question that cannot wait
Clinical trials are investigating senolytic treatments for specific conditions including kidney fibrosis and long COVID symptoms, with carefully monitored dosing and defined patient populations. For healthy people taking these drugs prophylactically — hoping to slow aging before any disease develops — the evidence base for long-term safety remains thin. The new brain findings make that gap more urgent. Whether similar effects occur in humans, at what doses, and after how much cumulative exposure are questions that research has not yet answered. Meanwhile, interest in senolytics continues to grow faster than the science.